Prioritizing Mental Health in South African Medical Schemes: Challenges and Opportunities

By HEOR Staff Writer

May 1, 2023

Medical schemes in South Africa are prioritizing mental health as a key component of managed care services. In 2019 CMS published a PMB definition guidelines for mental health emergencies.

“It is still concerning that beneficiaries of medical schemes attracted copayments as high as five (5%) for services such as a psychiatry benefit. Prior studies have also found that medical scheme members affected by mental illness and in most cases were discriminated against by funders. There needs to be a concerted effort to reprioritise mental health,” said Willie

A study analysed data from 2014-2018 and found the most prevalent mental disorders in South Africa in 2017 were anxiety and depression. However, only schizophrenia and bipolar mood disorder are the only conditions included in the PMB Chronic Diseases List (CDLs).

It is worrying that mental disorders like depression and anxiety are not covered under PMBs. We need a review of PMBs to include these conditions. A designated medical scheme provider should consider resource scarcity and co-payment rules.

Reference url

Recent Posts

Sandoz Mobile Health Initiative: Empowering Communities Through Accessible Care

By João L. Carapinha

May 5, 2026

Sandoz has launched the Sandoz mobile health initiative in Portugal through its “Sandoz em Marcha” project, sending a mobile health unit to 16 localities over two months to deliver free screenings and health educ...
Strategic Investment Boosts Medical Device Distribution in Africa
Amethis, Proparco, ccap.ai and Vertice management have completed the acquisition of Vertice MedTech Holdings, positioning the company for accelerated expansion as the ...
JNJ-4804 IBD Therapy Proves Effective for Refractory Inflammatory Bowel Disease
JNJ-4804 IBD therapy offers new hope for patients with hard-to-treat inflammatory bowel disease. This co-antibody treatment combines two proven mechanisms in a single injection. It targets IL-23 and TNF-α pathways at once. Recent Phase 2b results support its move into larger trials. Johnson &a...